Anticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells.
BACKGROUND: Histone deacetylase inhibitors (HDACIs) can inhibit cell proliferation, induce cell cycle arrest and stimulate apoptosis of cancer cells. MATERIALS AND METHODS: The effects of a novel HDACI, MS-275, on 4 endometrial cancer cell lines and normal human endometrial epithelial cells was investigated. Endometrial cancer cells were treated with various concentrations of MS-275 and its effect on cell growth, cell cycle, apoptosis and related measurements was investigated. RESULTS: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays showed that all endometrial cancer cell lines were sensitive to the growth inhibitory effect of MS-275, although the normal endometrial epithelial cells were viable after treatment with the same doses of MS-275 that induced growth inhibition in endometrial cancer cells. The cell cycle analysis indicated that their exposure to MS-275 induced the G0/G1 arrest of the cell cycle. Induction of apoptosis was confirmed by annexin V staining of externalized phosphatidylserine and loss of the transmembrane potential of mitochondria. This induction occurred in concert with altered expression of genes related to cell growth, malignant phenotype and apoptosis. CONCLUSION: These results raise the possibility that MS-275 may prove particularly effective in the treatment of endometrial cancer.[1]References
- Anticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells. Takai, N., Ueda, T., Nishida, M., Nasu, K., Narahara, H. Anticancer Res. (2006) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
